Redx Pharma (LSE:REDX) Retained Earnings : £-113.83 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Redx Pharma's retained earnings for the quarter that ended in Sep. 2023 was £-113.83 Mil.

Redx Pharma's quarterly retained earnings declined from Sep. 2022 (£-81.31 Mil) to Mar. 2023 (£-101.94 Mil) and declined from Mar. 2023 (£-101.94 Mil) to Sep. 2023 (£-113.83 Mil).

Redx Pharma's annual retained earnings declined from Sep. 2021 (£-64.23 Mil) to Sep. 2022 (£-81.31 Mil) and declined from Sep. 2022 (£-81.31 Mil) to Sep. 2023 (£-113.83 Mil).

Redx Pharma Retained Earnings Historical Data

The historical data trend for Redx Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma Retained Earnings Chart

Redx Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Retained Earnings

Get a 7-Day Free Trial

-34.14

-42.87

-64.23

-81.31

-113.83

Redx Pharma Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Retained Earnings	Get a 7-Day Free Trial															-64.23	-73.98	-81.31	-101.94	-113.83

Redx Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Redx Pharma (LSE:REDX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Redx Pharma (LSE:REDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.redxpharma.com

Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines